Evidence map›Paper›PMID 42326197›Full record

ArticleCureus2026

Novel FHL1 Mutation Associated With Reducing Body Myopathy.

Kyle W Ruffing, Marie Rivera-Zengotita, Lee Kugelmann, Morgan Jordan

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kyle W RuffingNeurology, University of Florida, Gainesville, USA.
Marie Rivera-ZengotitaPathology, University of Florida, Gainesville, USA.
Lee KugelmannNeurology, University of Florida, Gainesville, USA.
Morgan JordanNeurology, Cleveland Clinic, Port St. Lucie, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reducing body myopathy (RBM) is a rare X-linked myopathy caused by mutations in the FHL1 gene and characterized by intracytoplasmic aggregates that reduce menadione nitroblue tetrazolium. We report a 45-year-old female presenting with progressive proximal weakness of unknown etiology. Prior muscle biopsy and genetic testing were non-diagnostic. By repeating her muscle biopsy in a different muscle, we were able to correlate the biopsy findings with her genetic variant previously described as a variant of unknown significance. This is the first reported case of possible RBM associated with FHL1 c.401A>C (p.Gln134Pro). The case expands the genotypic spectrum of RBM and underscores the diagnostic value of repeated muscle biopsy.

Indexed as

adult-onset myopathyelectron microscopyfhl1muscle biopsynovel variantreducing body myopathy

Identifiers

PMID42326197
PMCPMC13281480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.